Background: Platelet-rich plasma (PRP) promotes regeneration of bone, presumably through the action of concentrated growth factors. However, it is not clear how PRP affects the inflammatory response. The purpose of this study was to analyze the growth factors in PRP and to study the effects of PRP on monocyte cytokine release and lipoxin A 4 (LXA 4 ) generation.
P
eriodontal wound healing involves a series of well-orchestrated cellcell interactions between gingival fibroblasts, epithelial cells, periodontal ligament fibroblasts, and osteoblasts, whereas disruption of the vasculature leads to fibrin formation, platelet aggregation, and release of several growth factors into the tissue from platelets. [1] [2] [3] [4] Oral surgical techniques involve the use of these factors in soft and mineralized tissue regeneration to regulate cellular events, such as proliferation, differentiation, chemotaxis, and morphogenesis of tissues and organs through auto-, para-, or endocrine mechanisms. 5, 6 Growth factors are deposited in the extracellular matrix, released during matrix degradation, and their subsequent interaction with surface receptors on the target cells activates intracellular signaling pathways that induce transcription of mRNA and proteins needed for the regenerative process. 5, 6 As a rich source of growth factors, platelet-rich plasma (PRP) is used in tissue engineering to increase the levels of growth factors by releasing them from intracellular stores. 7 Various growth factors are found in PRP; these include platelet-derived growth factor (PDGF) and transforming growth factor (TGF)-b1, both of which are involved in regulation of bone regeneration. 8 Thus, in addition to the growth factors released during periodontal wound healing, PRP could serve as a practical source for growth factors required in regenerative procedures. Because PRP is an autologous product, it also eliminates concerns about immunogenic reactions and disease transmission between individuals. 9 Animal studies and human trials demonstrated successful results in regenerative potential of PRP, suggesting that the administration of growth factors may be combined with tissue regeneration techniques in the repair of intrabony defects, furcations, and cyst cavities to improve the outcome of these treatments. [10] [11] [12] [13] [14] However, the reported results on the efficacy of this technique are limited and controversial. Some recent clinical reports 15 suggested that more rapid epithelization, denser and more mature bone with better organized trabeculae, and greater bone regeneration occurred when PRP was added to xenografts and synthetic graft materials, whereas some animal studies 16, 17 showed no beneficial additive effect of PRP. Several clinical case reports encouraged the use of PRP, whereas the number of controlled studies using PRP is limited, and the exact growth factor content in PRP and the biologic mechanisms mediated by PRP are still under investigation. A lack of post-surgical inflammation is a consistent anecdotal observation associated with the use of PRP.
The growth factor release potential by PRP is poorly described, and it is not known if PRP leads to any real inflammatory change. For example, release of TGF-b1, which is a major component of PRP, from degranulating platelets or secretion by infiltrating macrophages and fibroblasts is critical to initiation or progression of tissue repair; however, TGF-b1 actually may function to increase inflammation and retard wound closure. 18 Growth factors also have been linked to tumor growth, and this mechanism could involve the actions of monocyte/macrophages and inflammatory processes. 19, 20 In vitro and in vivo evidence suggests that macrophages secrete TGF-b1 with biphasic activity, acting as an anti-inflammatory mediator in addition to its proinflammatory properties. Thus, the reparative properties of TGF-b1 indicate a link between mechanisms governing resolution of inflammation and repair of damaged tissue. 21, 22 Resolution of inflammation also is mediated naturally by endogenous lipid molecules derived from cellular arachidonic acid called lipoxins (LXs). 23, 24 LXs are appreciated for their ability to promote resolution actively by retarding the entry of new neutrophils to sites of inflammation and promoting neutrophil apoptosis. LXs also are chemotactic for monocyte/macrophages that present with non-phlogistic phenotype and phagocytose apoptotic neutrophils and further promote healing and inflammation resolution. 25 One of the major routes for lipoxin A 4 (LXA 4 ) biosynthesis is the interaction of human neutrophils with platelets in the blood vessels. Cell-to-cell interactions promote hydroxylation of 12-hydroxyeicosatetraenoic acid (12-HETE) from platelets by 5-lipoxygenase (5-LO) from myeloid cells to yield 12-series LXs, 26 suggesting that platelets also could be involved actively in the resolution of inflammation. The purposes of this study were to identify the growth factor content in PRP, measure the cytokine/chemokine release by monocytes treated with PRP, investigate the chemotactic properties of PRP on human monocytes, and analyze the LXA 4 content in PRP.
MATERIALS AND METHODS

Subject Population and Blood Collection
Ten subjects were included in this study between September and October 2005. All subjects were medically and periodontally healthy volunteers recruited from the Clinical Research Center at Goldman School of Dental Medicine at Boston University (age range: 25 to 58 years; six females and four males). The study protocol was approved by the Institutional Review Board of Boston Medical Center, and informed consent was obtained. Smokers and individuals with systemic disease or history of anticoagulant, immunosuppressive, or antibiotic therapy in the last 6 months were excluded. After reviewing the medical and dental histories, a detailed oral examination was performed. Individuals with a history or evidence of periodontal disease were not included. Thirty milliliters of blood was collected by venipuncture of the antecubital vein into two vacutainer tubes ‡ with acid citrate dextrose prepared as described previously. 27 One tube of blood was used to isolate the peripheral blood monocytes, whereas the other tube was used for platelet isolation; 1 ml of blood was saved in an Eppendorf tube § as a whole blood (WB) sample.
Preparation of PRP, Cell Counting, Viability, and Activation Several systems are available to produce PRP. i ¶# ** [28] [29] [30] These systems use different protocols, but the end product is suitable for the same oral surgical applications, whereas the concentrations of growth factors may differ. We used a simple technique to generate PRP using common laboratory equipment. The blood samples from 10 individuals were transferred into 15-ml polystyrene tubes under sterile conditions and centrifuged at 500 · g for 10 minutes at room temperature. The upper plasma fraction and the buffy coat layer were collected carefully and centrifuged at 700 · g for 15 minutes. The platelets were pelleted, and the upper layer, which was clear and cell-free plasma, was transferred to another tube as the platelet-poor plasma (PPP). The pellet was used as the PRP. The samples were diluted in 1% ammonium oxalate to hemolyze mature erythrocytes; the unopette system † † and a double Neubauer hemocytometer ‡ ‡ were used for platelet count determination. The WB, PPP, and PRP samples were treated with 10% calcium chloride § § and bovine thrombin (low specific activity) ii mixture to activate the platelets. The samples were coagulated within a few seconds of activation and centrifuged at 5,000 · g for 10 minutes. The supernatant was collected and frozen at -70°C or used immediately in monocyte cultures.
Quantification of Growth Factors, Regulated on Activation, Normal T-Cell Expressed and Secreted (RANTES), and Interleukin (IL)-12 in WB, PPP, and PRP Samples from 10 individuals were assayed for PDGF-AB, TGF-b1, insulin-like growth factor (IGF)-I, RANTES, and fibroblast growth factor-basic (FGF-b) using commercially available enzyme-linked immunosorbent assay (ELISA) kits. ¶ ¶ The absorbance was read at the specified wavelength recommended by the manufacturer using a microplate reader. ## PDGF-BB, vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and IL-12 were determined by multiplexed sandwich immunoassays based on flowmetric technology*** in a 96-well filter plate. The antibody-coated beads were added to each well with samples or standards and incubated for 2 hours in the dark. The wells were washed with a vacuum manifold, and detection antibody conjugated to biotin was added. After incubation for 1 hour, beads were washed; this was followed by an incubation of 30 minutes with streptavidin conjugated to the fluorescent protein, R-phycoerythrin (streptavidin-RPE). After washing away unbound streptavidin-RPE, the beads were analyzed by bead-based multiplexing † † † to monitor the spectral properties of the beads while simultaneously measuring the amount of fluorescence associated with R-phycoerythrin. Data were analyzed using computer software. ‡ ‡ ‡ Monocyte-Mediated Cytokine and Chemokine Release Peripheral blood mononuclear cells were isolated by discontinuous Ficoll-Hypaque gradient centrifugation, as described previously, 31 from seven healthy individuals. Mononuclear cells were extracted and cultured in Roswell Park Memorial Institute (RPMI) 1640 supplemented with 5% human AB serum § § § for 2 hours in culture-coated 24-well plates. iii Nonadherent monocytes and non-phagocytic cells were washed, and adherent monocytes (= mononuclear phagocytes) were cultured further in RPMI 1640 + 5% human AB serum for 18 hours in the presence or absence of PRP obtained from the same individual at 20% concentration. IL-1b, -6, -8, -12 (p40/70) and -13, monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein (MIP)-1a and -1b, RANTES, and tumor necrosis factor (TNF)-a were detected by multiplexed sandwich immunoassays based on flowmetric technology ¶ ¶ ¶ as described above.
Monocyte Chemotaxis in Response to PRP Monocytes were isolated from mononuclear cells of three healthy individuals using magnetic cell sorting (MACS) by depletion of non-monocytes (negative selection). Non-monocytes were magnetically labeled indirectly with a cocktail of biotin-conjugated monoclonal antibodies, as the primary labeling reagent, and anti-biotin monoclonal antibodies conjugated to microbeads, as the secondary labeling reagent. The magnetically labeled non-monocytes were depleted by retaining them on a MACS LS column in the magnetic field of the separator, ### whereas the unlabeled monocytes passed through the column. The highly pure unlabeled monocytes were used in chemotaxis experiments. Using the 48-well microchemotaxis chamber,**** 25 ml 1% to 30% PRP in glucose gelatine veronal buffer (GGVB) ++ were placed carefully in the lower wells of the chamber in triplicate. We used GGVB ++ as a negative control for calculating random migration values and N-formyl-methionyl-phenylalanine (fMLP, 10 -7 M) as a positive control. 32 RANTES † † † † was tested at a concentration of 15 to 45 ng/ml, which was the concentration of RANTES in PRP. The polycarbonate membrane filters (5-mm pore size) were placed over the lower wells followed by the gasket and top plate. The monocytes were diluted in warm GGVB ++ at a concentration of 5 · 10 6 cells/ml. In the upper plate of the chamber, 50-ml cell suspension was placed in each well. The filled chamber was incubated at 37°C with 5% CO 2 for 3 hours. After incubation, the filter membrane was fixed in neutral buffered formalin overnight. Hematoxylin staining of the filter membrane was performed, and it was mounted on a slide for evaluation. J
LXA 4 Assay
To measure the LXA 4 content in PRP, total lipid was extracted from PRP or WB preparations from 10 healthy individuals by diluting the sample in methanol (1:2; volume/volume). Deionized water was added, and the pH was adjusted to 3.5 with 1 N hydrochloric acid. Cartridges ‡ ‡ ‡ ‡ were conditioned with methanol followed by water. The diluted sample was applied to the cartridge; the cartridge was washed with water followed by hexane, and the sample was eluted with methyl formate. The elution was exposed to a continuous stream of nitrogen to evaporate the methyl formate and to minimize acyl migration. The dried sample was reconstituted with extraction buffer and introduced to competitive ELISA § § § § as described previously. 33 LXA 4 concentration in monocyte supernatants also was analyzed by this method. The plate was read at 450 nm using a microplate reader.
Statistical Analysis
All data were analyzed by one-way analysis of variance and corrected for multiple measures by Bonferroni correction. All values are reported as mean -SD. Statistical significance was set at 0.05. Table 1 shows the platelet counts in WB, PRP, and PPP. PRP led to a 5.2-fold concentration of platelets (range, 2.8 to 8.8) demonstrating a large variability between individuals. PPP samples also were tested; platelet counts in PPP were negligible. We evaluated WB, PPP, and PRP samples for PDGF, TGF-b1, IGF-I, EGF, VEGF, and FGF-b. Figure 1 shows that PDGF-AB and -BB levels were significantly higher in PRP compared to PPP (P <0.0001). PDGF content in PPP was minimal (344 -211 pg/ml). Similar results were obtained for TGF-b1; PRP had significantly higher levels of TGF-b1 compared to WB and PPP (P <0.0001). PRP did have an increase in IGF-I concentration over WB (P <0.05); however, there was no significant difference between PRP and PPP (P >0.05). In addition to these previously reported growth factors, we analyzed EGF, VEGF, and FGF-b in PRP. A statistically significant difference was seen in the PRP content of EGF, VEGF, and FGF-b compared to PPP and WB. PRP led to a 5.6-fold increase in EGF levels, a 4.4-fold increase in VEGF levels, and a nine-fold increase in FGF-b levels compared to WB (Fig. 1 ). Table 2 shows the monocyte-mediated cytokine/ chemokine release in the presence or absence of PRP. TNF-a; IL-1b, -6, -8, and -13; and MIP-1a and -1b levels were not statistically significantly different compared to cells that were not treated with PRP (P >0.05). IL-12 and RANTES were increased significantly, whereas MCP-1 levels were decreased significantly compared to the cells that were not treated with PRP (P <0.05). Because platelets also could be a rich source of RANTES, 34 we analyzed PRP, PPP, and WB samples for their RANTES content. PRP had significantly higher RANTES levels compared to PPP and WB (P <0.0001; Fig. 2A ). There also was a significant increase in IL-12 concentration in PRP compared to WB (P <0.05), whereas PRP and PPP levels were similar (Fig. 2B) . Figure 3A shows the chemotactic effect of PRP on monocytes at concentrations between 1% and 30%. PRP had a dose-dependent effect on monocyte chemotaxis. The maximum effect was seen at 5% concentration; the curve flattened into a plateau at concentrations of 10% to 30%, suggesting that PRP leads to significant chemotaxis on monocytes. Because PRP contains significant levels of RANTES ( Fig. 2A) , we then tested the RANTES-mediated chemotaxis to evaluate how much of PRP's chemotactic effect could be attributable to RANTES. This chemokine significantly stimulated monocyte chemotaxis at concentrations of RANTES found in PRP (Fig. 3B) . There was no dose-dependent increase in its effect at doses tested, whereas RANTES-induced monocyte chemotaxis was less than the overall induction observed in response to PRP. This suggested that RANTES, in part, is responsible for this effect. fMLP was used as a positive control, and PRP's effects were comparable to those of fMLP.
RESULTS
Platelet Counts and Growth Factors in PRP
Cytokine and Chemokine Release From Monocytes in Response to PRP
PRP-Induced Monocyte Chemotaxis
PRP as a Source of LXA 4 Because it was shown that platelets have the capacity of generating endogenous anti-inflammatory compounds, such as lipoxins, 26 we tested the LXA 4 content as an anti-inflammatory mediator in PRP. When monocytes were treated with PRP, there was an increase in LXA 4 in culture supernatants but this difference was not statistically significant (Fig. 4A) . To measure the LXA 4 levels in PRP, we analyzed the PRP and WB samples directly. PRP had higher LXA 4 levels compared to WB, and this 2.2-fold difference was statistically significant (P <0.001; Fig. 4B ). There was no difference between PPP and WB (data not shown).
DISCUSSION
We demonstrated that PRP led to significantly increased levels of growth factors ( Fig. 1) and significantly suppressed inflammation by promoting secretion of LXA 4 . PDGF-BB, TGF-b1, and IGF-I were reported previously in PRP, 35 and strong mitogenic and anabolic properties have been attributed to them. These growth factors stimulated the proliferation of fibroblasts and periodontal ligament cells, as well as extracellular matrix formation, and promoted collagen and total protein synthesis 36 while stimulating the synthesis of hyaluronate from gingival fibroblasts. 37 PDGF-BB also demonstrated a significant stimulation of adherence of periodontal ligament cells to root surfaces 38 while reducing the inhibitory effects of lipopolysaccharide on gingival fibroblast proliferation. 39 TGFb1 is known to have an inhibitory effect on epithelial cell proliferation, 40 and IGF-I is an important molecule that has strong effects on periodontal ligament fibroblast mitogenesis and protein synthesis in vitro. 41 High levels of IGF-I are synthesized and secreted by osteoblasts, and, therefore, may regulate bone formation in an autocrine manner. 42 In our study, it was of interest that IGF-I levels in PRP were not significantly different from PPP, suggesting that other cell types could be responsible for the release of this growth factor. Indeed, IGF-I is synthesized in the liver, smooth muscles, and placenta and is transported via the plasma. 43 In addition to confirming the previous findings on these growth factors, we demonstrated that PRP is a significant source of EGF, VEGF, and FGF-b. EGF was found to play an important role in regulating the growth of many ectodermal-and mesodermalderived cells, and FGF-b is chemotactic and mitogenic for periodontal ligament fibroblasts; 44 this abrogates the synthesis of type-I collagen, which is one of the most common extracellular matrices of the periodontium and is essential for calcified nodule formation. 45 VEGF was found to be critical for the formation of new blood capillaries in healing wounds and is important for the integrity of the endothelial lining of the vasculature. 46 Thus, collectively, PRP delivers significant amounts of growth factors, which are essential to wound healing and regeneration, and our results confirmed the previous reports on its potential as a good source of growth factors. Our findings also demonstrated that in addition to increased delivery of growth factors to the wound area, PRP enhances the regenerative processes through antiphlogistic activity as demonstrated by the lack of macrophage activation, inhibition of MCP-1, increased delivery of RANTES, and release of LXA 4 . The macrophage is essential for wound healing and plays a central role in the inflammatory process and regulation of regenerative repair process. Many cytokines and chemokines are released from macrophages during inflammation and wound healing. We showed that monocyte cytokine and chemokine release, with the exception of RANTES and IL-12, did not increase in response to PRP, demonstrating that PRP promotes non-phlogistic activity of monocytes (Table 2) . Increased levels of RANTES in monocyte cultures treated with PRP were of platelet origin, as shown by further investigation and significant differences in RANTES in PRP compared to WB and PPP ( Fig. 2A) . RANTES, a chemokine that is regulated upon activation, expressed normally in T cells, and known as chemokine (C-C motif) ligand 5 (CCL5), could have a dual role in inflammation. As a mediator of the inflammatory process, RANTES increases the adherence of monocytes to endothelial cells, 47 which, in turn, could be a potent chemoattractant to and activator of monocytes. 33, 48 RANTES also can inhibit the release of histamine from basophils induced by several cytokines, 49 leading to an inhibition of inflammatory processes and a shift in the wound environment toward repair and healing. Platelet-mediated RANTES originates from the alpha granules in platelets and could have beneficial effects in controlling the inflammatory processes, as demonstrated by studies in AIDS patients where there is a decreased concentration of RANTES released from platelets. 50 Therefore, our findings suggested that monocyte/ macrophage and platelet-mediated RANTES release may act at different stages of activation or resolution of inflammation, whereas PRP delivers considerable amounts of RANTES to the wound. To test the chemotactic properties of PRP, we designed experiments so that fMLP was used as a positive control, RANTES was tested as a monocyte chemoattractant, and the chemotactic properties of PRP were analyzed in a dose-response fashion. PRP had a strong chemotactic effect on monocytes at 5% concentration and above. The same experiment showed that RANTES, at concentrations equal to the concentration in PRP, had significant chemotactic effects on monocytes; this suggested that RANTES, in part, is responsible for PRP-induced chemotaxis. However, PRP's effect is not attributable to RANTES alone, and it may be linked to other factors that require further investigation. To this end, LXA 4 could account for some of this effect as described in previous studies, 32 further suggesting that increased monocyte/macrophage recruitment to the wound area could promote healing and regeneration in PRP-mediated processes. IL-2 was another inflammatory mediator that was increased in our monocyte cultures treated with PRP. When we analyzed the concentration of IL-12 in PRP, WB, and PPP, we found that the source of IL-12 was the plasma itself because there was no difference between PRP and PPP (Fig. 2B) ; this suggested that multiple cells and processes in peripheral blood could lead to increased IL-12 generation. Meanwhile, PRP led to a significant inhibition in MCP-1 release by monocytes. MCP-1 is a member of the CC chemokine family and is produced by various cells, including monocyte/ macrophages, in response to proinflammatory stimuli. 51 In monocytes, MCP-1 induced chemotaxis and the respiratory burst, rapid induction of arachidonic acid release, and changes in Ca 2+ concentration. 52, 53 Thus, these findings suggested that in addition to the increased growth factor release, PRP suppresses MCP-1 release by monocytes. These pathways require further investigation, but, within the limits of this study, suggest that these properties of PRP further reduce monocyte-mediated inflammation and enhance wound healing.
It is clear from years of research in wound healing and tissue regeneration that excess inflammation or chronic inflammation inhibits regeneration. Our findings demonstrated that platelet-derived LXA 4 was elevated, which drives inflammation to resolution. LXA 4 increased TGF-b1 in resolving exudates 25 while promoting the non-phlogistic infiltration of monocytes that seems to be required for wound healing 32 and further stimulated macrophages to ingest and clear apoptotic neutrophils. 54 Therefore, the increased amounts of LXA 4 in PRP might augment the actions of the reparative properties of TGF-b1 and justify the use of PRP in periodontal surgical procedures. It also explains the favorable wound healing observed clinically when PRP was applied. 7, 55 CONCLUSIONS PRP has the potential and capability to promote periodontal regeneration through various mechanisms.
While increasing the concentrated delivery of various growth factors, PRP acts as an anti-inflammatory agent by production of RANTES, blocking MCP-1 release from monocytes, and its concentration of LXA 4 , suggesting that PRP facilitates healing by controlling the local inflammatory response.
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